Kornimate/medical-research-clean huggingface dataset:
development of predictive biomarkers

Conditions: Type1diabetes

Summary: investigators aim to further the understanding of the various factors that govern the progression of beta-cell death in individuals recently diagnosed with type 1 diabetes (t1d). specifically, the investigators wish to examine the utility of plasma-induced signatures and other measures as predictive biomarkers for the rate of c-peptide decline in individuals with recent onset t1d. persistent c-peptide in individuals with t1d reflects some degree of β-cell function and is clinically associated with a reduction in both severe hypoglycemic events and microvascular complications such as diabetic nephropathy and retinopathy. there is significant heterogeneity in the rate of c-peptide decline in individuals with t1d, reflective of the complex disease process. for example, \~10% of individuals have no discernable fall in stimulated c-peptide after two years from clinical diagnosis as compared to other individuals with very rapid c-peptide decline. it is currently impossible to predict how long, and to what extent, someone will have residual c-peptide production. this complicates clinical management but also the design and interpretation of t1d β-cell preservation trials. the "gold standard" outcome measure of any t1d β-cell preservation trial is the stimulated c-peptide to a mixed meal tolerance test (mmtt). given the variability in this measure, intervention studies must include more subjects over a longer period of time. this slows the rate of scientific discovery and increases cost. this study aims to define the governing mechanisms of post-onset t1d disease trajectory. understanding the trajectory of the disease may lead to the development of biomarkers to predict disease progression and therapies that could reverse or prevent the development of type 1 diabetes.


Eligibility criteria:
inclusion criteria: 1. males and females 5-17 years of age with a clinical diagnosis of t1d 2. t1d diagnosis date between 1-3 months at the time of study visit 2 (baseline visit) 3. treatment naïve of any immunomodulatory agent 4. receiving routine out-patient diabetes care at the chw diabetes clinic exclusion criteria: 1. presence of severe, active disease that requires the use of chronic medication, with the exception of well-controlled autoimmune thyroiditis/hypothyroidism or celiac disease that is well-controlled on a gluten free diet. 2. diabetes other than t1d 3. chronic illness known to affect glucose metabolism 4. psychiatric impairment, with the exception of well-controlled depression or anxiety, that will affect the ability to participate in the study 5. female participants of child-bearing age with reproductive potential must not be knowingly pregnant 6. any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results
canthaxanthin retinopathy: a long-term observation

Conditions: Canthaxanthin Retinopathy

Summary: canthaxanthine is a naturally occurring carotenoid that has been a popular over-the-counter oral artificial tanning agent in europe, canada, and australia since 1979. it is also used at low dosage as a food-colouring agent and as a therapeutic agent for photosensitivity disorders such as erythropoietic protoporphyria. canthaxanthin retinopathy was first described in 1982 by cortin et al. in germany the office of the federal board of health refused the permit for oral tanning agents containing canthaxanthine in 1985. at that time the long-term course of the disease was not known. 25 years later the investigators did these long-term follow-up examinations.


Eligibility criteria:
inclusion criteria: * patients using oral tanning agents for at least 2 months. * patients of 18 years or older exclusion criteria: * none.

Keywords: canthaxanthin retinopathy
effects of 100% medical grade manuka honey on tympanic membrane reconstruction healing.

Conditions: Otitis Media, Suppurative; Tympanic Membrane Perforation

Summary: throughout history, honey has been recognized for its healing properties. the use of honey for its medicinal properties dates back to 2200 bce. the purpose of this clinical trial is to learn about the healing effects of 100% medical grade manuka honey in participants with chronic suppurative otitis media of the mucosal type. the main question it aims to answer is: can 100% manuka honey given at the time of tympanoplasty improve the re-epithelialization (healing process) of the tympanic membrane compared to controls? participants in the intervention group will receive a wound dressing of 100% medical grade manuka honey after reconstructive surgery of the tympanic membrane. researchers will compare the intervention group to the control group to see healing process.

the aim of the present study is to conduct a randomized clinical trial to compare the effect of 100% sterile manuka honey on re-epithelialization of the tympanic membrane post tympanoplasty compared to the control group. the investigation will involve 64 participants with chronic suppurative otitis media of the mucosal type, who will be randomly put into two groups (intervention or control), where the intervention group will receive a dressing of 100% sterile manuka honey during surgery. results of this study will inform practitioners as to the potential benefits of 100% sterile manuka honey on the re-epithelialization of the tympanic membrane.

Eligibility criteria:
inclusion criteria: * participants of 18 - 45 years of age. * participants with chronic suppurative otitis media of the mucosal type. * provision of signed and dated informed consent form. stated willingness to comply with all study procedures and availability for the duration of the study. exclusion criteria: * participants who previously received surgical therapy for chronic suppurative otitis media or have recurrent or residual disease. * participants with anatomical pathology results showing and/or suspecting a tumor.

Keywords: chronic suppurative otitis media manuka honey wound healing re-epithelialization tympanoplasty tympanic membrane
analysis of dendritic phenotype and function of patients receiving vegf-trap on vgft-st-0202

Conditions: Lymphoma; Solid Tumor

Summary: rationale: studying the dendritic cells in samples of blood from patients with cancer receiving aflibercept may help doctors learn about the effect of aflibercept on dendritic cells. purpose: this laboratory study is evaluating dendritic cells in patients with advanced solid tumors or non-hodgkin lymphoma receiving aflibercept on clinical trial vgft-st-0202.

objectives: * evaluate the effect of in vivo aflibercept on the presence of different populations of dendritic cells (dc) and immature cells (imc) in the peripheral blood of cancer patients by characterizing the time course (kinetics) of the improvement in antigen presenting cell (apc) phenotype (decline in dc/imc ratio) occurring early and late after aflibercept administration. * evaluate the effect of aflibercept administration on dc function based on ability to stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic t cell responses (influenza) by characterizing the time course (kinetics) of the improvement in apc function occurring early and late after aflibercept administration. * explore the relationship of baseline aflibercept level and host apc phenotype. outline: this is a multicenter study. patients undergo phlebotomy and blood collection at baseline and on days 15, 29, and 57. samples are analyzed for dendritic cell phenotype, subpopulations, maturation status, and function in terms of ability to activate autologous t cells.

Eligibility criteria:
inclusion criteria: * diagnosis of advanced solid tumor or non-hodgkin lymphoma and enrolled on clinical trial vgft-st-0202 * hemoglobin ≥ 10 g/dl * willing to undergo phlebotomy exclusion criteria: * none listed prior concurrent therapy: * see disease characteristics

Keywords: unspecified adult solid tumor, protocol specific recurrent adult burkitt lymphoma stage iv adult burkitt lymphoma recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma stage iv adult diffuse large cell lymphoma stage iv adult diffuse mixed cell lymphoma stage iv adult diffuse small cleaved cell lymphoma recurrent adult immunoblastic large cell lymphoma stage iv adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma stage iv adult lymphoblastic lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma stage iv grade 1 follicular lymphoma stage iv grade 2 follicular lymphoma stage iv grade 3 follicular lymphoma recurrent mantle cell lymphoma stage iv mantle cell lymphoma recurrent marginal zone lymphoma splenic marginal zone lymphoma stage iv marginal zone lymphoma nodal marginal zone b-cell lymphoma extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue recurrent small lymphocytic lymphoma stage iv small lymphocytic lymphoma
ureteric jet doppler waveforms in patients with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: urinary dysfunction is very common in individuals with spinal cord injury. the urine flowing from the collecting ducts to the renal calyx stretches the calyces. ans controlled peristaltic contractions originate in the proximal renal pelvis and travel down the ureters, pushing urine from the renal pelvis towards the bladder. the urine bolus delivered from the kidneys through the peristaltic contraction of the ureter creates an image called ureteric jet. using the doppler analysis of ureteral jets, previous studies have examined the changes in the ureteric jet pattern in pathological conditions such as the diagnosis of normal ureteral physiology.

this cross-sectional study was conducted at a tertiary rehabilitation center. eighteen spinal cord injury patients who met the inclusion criteria and 24 healthy volunteers were included in the study. the appearance of üreteric jet form and bladder wall thicknesses were obtained by urinary doppler ultrasound both in patient and control groups. detrusor pressure and bladder volume were measured only in patient group during urodynamic assessment.

Eligibility criteria:
the case group inclusion criteria: * with signs of upper motor neuron lesion, * suprasacral spinal cord injury, * normal urinary ultrasound findings * planned urodynamics exclusion criteria: * neurological disease other than spinal cord injury * urinary tract infection * urinary obstruction * history of urinary tract stones * diabetes, hypertension * history of urinary surgery, * sacral injury * second motor neuron lesions (such as cauda equina, or cauda conus) the control group inclusion criteria: • normal urinary ultrasonography exclusion criteria: * neurological disease * urinary tract infection * urinary obstruction * history of urinary tract stones * diabetes, hypertension
manual therapy in parkinson's disease

Conditions: Parkinson Disease

Summary: an experimental study will be carried out to examine how a manual therapy protocol can influence a series of parameters related to motor and non-motor symptoms in patients who have parkinson's disease / parkinsonism. to do this, an intervention will be carried out that will last a minimum of 6 weeks. in addition to their ongoing treatment, the study subjects will receive a maximum of 2 sessions of manual therapy each week. they will undergo a series of measurements both before and after the intervention related to gait, balance, non-motor symptoms, and some more specific parameters of gait. the study's main objective is to obtain information about possible treatment models based on manual therapy for parkinson's disease. it is also hoped to compile a series of results that will lead to conclusions and benefit the development of physiotherapy for this disease. it is also hoped that this will help those affected so that the treatment is as comprehensive as possible and that the physiotherapist can use as many tools as are available to them to address the pathology.


Eligibility criteria:
inclusion criteria: * people aged between 40 and 75 who voluntarily agree to take part in this study exclusion criteria: * people with dementia and established cognitive impairment with scores on the montreal cognitive assessment test (moca) of less than 25
topical cream sng100 for treatment in moderate atopic dermatitis subjects.

Conditions: Atopic Dermatitis

Summary: the investigators aimed to understand better the efficacy in a randomized, double-blind, intraindividual design trial in 66 participants with ad treated with sng100, and 2 different strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.


Eligibility criteria:
inclusion criteria: 1. males or females 6 years old or older with a diagnosis of moderate atopic dermatitis confirmed by a dermatologist 2. any child age 6 to 18 with a diagnosis of moderate atopic dermatitis confirmed by a dermatologist, together with the child's parent/guardian. written informed consent must be given by parent/guardian. 3. capable of complying with study requirements and study procedure. 4. investigator global assessment (iga) of 3. 5. the severity of atopic dermatitis will be defined as moderate by scorad range of 26-50 and easi range of 7.1-21 points. 6. child-bearing potential women must use a proper contraception method. exclusion criteria: 1. as determined by the study doctor, a medical history that may interfere with study objectives. 2. atopic dermatitis lesions that occur only on the face and scalp. 3. presence of a secondary infection with bacteria, fungi, or virus. 4. recent or current participation in another research study. 5. females who are breastfeeding, pregnant, or with plans to get pregnant during the participation in the study. 6. prior wound, tattoo, pigmentation or infection in the treated area.
individualised blood pressure targets versus standard care among critically ill patients with shock

Conditions: Critical Illness; Shock

Summary: aim the aim of the proposed rct is to determine effectiveness of a strategy, where map (mean arterial blood pressure) targets during vasopressor therapy for shock in icu are individualized based on patients' own pre-illness map that would be derived as an average of up to five most recent pre-illness blood pressure readings. hypothesis we hypothesize that targeting a patient's pre-illness map during management of shock can minimize the degree of map-deficit (a measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in icu. endpoints the primary endpoint will be the all-cause mortality rate at day 14. secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (make-14), renal replacement therapy (rrt) free days until day 28, and 90-day all-cause mortality. significance to date no major rct has tested this strategy among icu patients with shock. this pivotal trial will provide evidence to fulfil a crucial knowledge gap regarding a common and a fundamental intervention in critical care.


Eligibility criteria:
inclusion criteria: * icu patients aged greater than or equal to 40 years * the patient is deemed to be in shock, defined as clinician-initiated vasopressor/inotropic therapy and supported by any of the following within the last 24 hours: * lactate level greater than or equal to 2 mmol/l or base deficit greater than or equal to 3 mmol/l, * urine output less than or equal to 0.5 ml/kg/h or \<40 ml/h for 2 or more consecutive hours * respiratory rate \>22 per minute * altered mentation (glasgow coma score \<14) exclusion criteria: * patients who are moribund, or have documented not-for-resuscitation orders * at least 24 hours have lapsed from the time of initiation of vasopressor or inotropic support * patients who are either receiving or are deemed to imminently need renal replacement therapy. * patients who already have an increase in serum creatinine of \>350 µmol/l from baseline. * end stage renal disease * patients where trauma is the main reason for the current icu admission. * previously enrolled in the react shock rct * pregnancy, if known * active bleeding (clinical suspicion or \>2 packed red blood cells within last 24 hours) * insufficient (less than two) pre-illness bp readings are available. * patients on extracorporeal support (such as extracorporeal membrane oxygenation, intra-aortic balloon pump, or ventricular assist device). * potential contraindications to either higher or lower bp targets (including but not limited to) * cerebral perfusion pressure guided therapy e.g. intracranial hemorrhage or subarachnoid hemorrhage or traumatic brain injury * abdominal perfusion pressure guided therapy * aortic injury (e.g. dissection or post-operative) * post cardiac surgery * any other condition requiring higher or lower bp target specifically

Keywords: relative hypotension
a study to investigate pharmacokinetic drug interaction and safety of telmisartan/amlodipine and rosuvastatin

Conditions: Hypertension; Hyperlipidemia

Summary: this is a phase 1, open label, two-cohort, single-sequence, crossover study

this is a phase 1, open label, two-cohort, single-sequence, crossover study to investigate the pharmacokinetic drug interaction and safety of telmisartan/amlodipine and rosuvastatin in healthy male volunteers.

Eligibility criteria:
inclusion criteria: * healthy male with body mass index(bmi) between 18.5 and 28 kg/m2 * who has not suffered from clinically significant disease * provision of signed written informed consent exclusion criteria: * history of and clinically significant disease * a history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs * administration of other investigational products within 3 months prior to the first dosing * volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ecgs, or vital signs * sitting blood pressure meeting the following criteria at screening: 160 ≥ systolic blood pressure ≤100 (mmhg) and 95 ≥ diastolic blood pressure ≤ 60 (mmhg)
urinary actin, as a potential marker of sepsis-related acute kidney injury

Conditions: Sepsis; Acute Kidney Injury Due to Sepsis

Summary: in our study, 17 septic, 43 sepsis-related acute kidney injury and 24 control patients were enrolled. blood and urine samples were collected at the intensive care unit from acutely diagnosed septic and sepsis-related acute kidney injury patients at three time points (t1-3): t1: within 24 hours after admission; t2: second day morning; t3: third day morning of follow-up. patients with malignancies needing palliative care, end-stage renal disease or kidney transplantation were excluded. not more than one sample (venous blood, midstream spot urine) was collected from control patients. serum and urinary actin levels were determined by quantitative western blot. urinary actin concentrations were expressed as µg/l, while serum actin levels were expressed as mg/l. data were compared with laboratory and clinical parameters. patients were categorized by the sepsis-3 definitions and 30-day mortality data were investigated.

actin is a globular protein present in every cell with a 42 kilodalton molecular mass. it plays an important role in muscle contraction while being an essential component of the cytoskeleton as well. several proteins (e.g. gelsolin, gc-globulin) bind actin in the circulation during the physiological cell turnover, thus making its urinary appearance unlikely. however, recent studies indicate that actin could be detected in the urine of kidney-transplant patients with acute kidney injury. therefore, the main focus of our research was the detection and measurement of actin in the blood and urine in patients with sepsis or sepsis-related acute kidney injury, as the early recognition of kidney injury - especially in sepsis - is essential in the aspect of therapy and survival.

Eligibility criteria:
inclusion criteria: * sepsis * sepsis-related acute kidney injury exclusion criteria: * malignancies needing palliative care * end-stage renal disease * kidney transplantation * under 18 years of age * unobtainable consent

Keywords: sepsis-3 acute kidney injury urinary actin western blot
cold application effects on nausea and vomiting after laparoscopic cholecystectomy

Conditions: Laparoscopic Cholecystectomy; Postoperative Nausea and Vomiting

Summary: this clinical trial aims to test the effect of cold application on postoperative nausea and vomiting.

nausea and vomiting seen within the first 24 hours after surgery are defined as "post-operative nausea and vomiting (pobk). postoperative nausea and vomiting are one of the most common complications of anesthesia. it has been reported that the risk of nausea and vomiting is particularly high after laparoscopic cholecystectomy. it is stated that vagal stimulation and pneumoperitoneum process may trigger this situation in laparoscopic surgeries. nausea and vomiting after surgery is a very uncomfortable situation for the patient. there are several pharmacological methods to prevent and treat pobk. however, it is stated that the non-pharmacological approach should also be brought to the fore. it is stated that cold reduces molecular activity and causes vasoconstriction. it is stated that cold can slow down the blood flow to the vomiting center in the medulla oblongata and the progression of nausea and vomiting can be slowed down. in this way, it is thought that it will contribute to increasing patient satisfaction and providing cost-effective care. the study will conduct as a prospective randomized controlled trial. after obtaining verbal and written consent from the patients before and after the surgery, the study will conduct with various data collection forms. these forms are; the patient data collection form, numerical evaluation scale, preoperative apfel risk score evaluation form, postoperative nausea severity evaluation form, and perceived effectiveness of the ice pack forms will use. laparoscopic cholecystectomy will perform and all cases meeting the inclusion criteria will evaluate. patients will randomize. the ice pack will apply in group-i (n=27), and group ii (n=27) will be the control group. an ice pack will be applied to the posterior upper neck regions of patients with nausea in group-i, at an interval of 5 minutes. the vital signs of the patients will be recorded. the severity of nausea and pain of the patients will be evaluated with a numerical rating scale. the effectiveness of its application as perceived by the patient will be evaluated. in the control group, the severity of nausea and pain will be determined by using a numerical evaluation scale in patients with postoperative nausea. vital signs will be recorded at this stage. standard procedures will be applied to these patients within the scope of nursing practices.

Eligibility criteria:
inclusion criteria: * inclusion in asa (american society of anesthesiologists) i-ii-iii class * being over 18 years old * having received general anesthesia * preoperative pain value of 6 or less exclusion criteria: * severe nausea in the preoperative period * being hypothermic in the postoperative period * having had head and neck surgery * taking prophylactic antiemetics * postoperative pain value of 7 and above

Keywords: laparoscopic cholecystectomy postoperative nausea and vomiting cold application